{"id":"primec","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":{"setId":"aaa27998-0db4-4884-80f7-43c9bc6815a9","title":"STILA ILLUMINATE AND SHINE (OCTINOXATE, AVOBENZOATE, AND OCTISALATE) KIT [STILA STYLES, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PrimeC contains vitamin C and other micronutrients intended to enhance immune response and provide antioxidant protection. The formulation is marketed as a supportive nutritional product rather than a pharmaceutical drug with a specific molecular mechanism of action.","oneSentence":"PrimeC is a nutritional supplement formulation designed to support immune and antioxidant function through a combination of vitamins and micronutrients.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T02:06:09.467Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Immune support and antioxidant supplementation"}]},"trialDetails":[{"nctId":"NCT05357950","phase":"PHASE2","title":"A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS","status":"COMPLETED","sponsor":"NeuroSense Therapeutics Ltd.","startDate":"2022-05-31","conditions":"Amyotrophic Lateral Sclerosis, ALS","enrollment":69},{"nctId":"NCT06185543","phase":"PHASE2","title":"A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease.","status":"UNKNOWN","sponsor":"NeuroSense Therapeutics Ltd.","startDate":"2023-11-19","conditions":"Alzheimer Disease","enrollment":20},{"nctId":"NCT05436678","phase":"PHASE1","title":"A Multiple-Dose PK Study to Evaluate the Comparative Bioavailability of PrimeC Tablets to Ciprofloxacin Tablets Co-administered With Celecoxib Capsules, in Healthy Adult Subject","status":"COMPLETED","sponsor":"NeuroSense Therapeutics Ltd.","startDate":"2022-07-26","conditions":"Pharmacokinetics","enrollment":19},{"nctId":"NCT05232461","phase":"PHASE1","title":"A Pilot Study to Evaluate the PK Profile of PrimeC-ER Tablets in Healthy Adult Subjects","status":"COMPLETED","sponsor":"NeuroSense Therapeutics Ltd.","startDate":"2022-04-08","conditions":"Pharmacokinetics","enrollment":12},{"nctId":"NCT04090684","phase":"PHASE1","title":"Ciprofloxacin/Celecoxib Combination in Patients With ALS","status":"COMPLETED","sponsor":"NeuroSense Therapeutics Ltd.","startDate":"2019-12-09","conditions":"ALS (Amyotrophic Lateral Sclerosis)","enrollment":10},{"nctId":"NCT04165850","phase":"PHASE2","title":"Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS","status":"COMPLETED","sponsor":"NeuroSense Therapeutics Ltd.","startDate":"2019-11-25","conditions":"Amyotrophic Lateral Sclerosis, ALS","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"PrimeC","genericName":"PrimeC","companyName":"NeuroSense Therapeutics Ltd.","companyId":"neurosense-therapeutics-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PrimeC is a nutritional supplement formulation designed to support immune and antioxidant function through a combination of vitamins and micronutrients. Used for Immune support and antioxidant supplementation.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}